JERUSALEM , Jan. 4, 2024 /PRNewswire/ — Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company focused on development of inflammation and immunology (I&I) biological products, today published a letter from its CEO, Amir Reichman, addressing the Company’s 2023 accomplishments, including successful preclinical trial results of its anti-IL-17 NanoAb psoriasis therapy and 2024 plans. The Company will host a… Continue reading Scinai Immunotherapeutics CEO Issues Letter to Shareholders
Tag: Possible_Terrorism_Warfare
Clean Technica: 27% BEV Share In China!003180
Sign up for daily news updates from CleanTechnica on email. Or follow us on Google News! Plugin vehicles are all the rage in the Chinese auto market. Plugins scored more than 872,000 sales last month, up 39% year over year (YoY), which is this market’s fourth record month in a row. And expect the last… Continue reading Clean Technica: 27% BEV Share In China!003180
Polar Bear Dies From Bird Flu
“This is the first polar bear case reported, for anywhere.” Iced Out Polar bears can’t catch a break. First, you have Arctic ice decreasing year after year due to climate change. And oil drilling that can potentially destroy their snowy dens. And now there’s another thing to worry about: the bird flu. Alaska officials confirmed last… Continue reading Polar Bear Dies From Bird Flu
Tesla Strike in Sweden Highlights a Culture Clash
The Tesla technicians who walked off their jobs in Sweden say they still support the mission of the American company and its headline-grabbing chief executive. But they also want Tesla to accept the Swedish way of doing business. They call it the Swedish Model, a way of life that has defined the country’s economy for… Continue reading Tesla Strike in Sweden Highlights a Culture Clash
Ellomay Capital Enters into an Agreement to Sell the Talmei Yosef Solar Facility
TEL-AVIV, Israel, Jan. 3, 2024 /PRNewswire/ — Ellomay Capital Ltd. (NYSE American: ELLO) (TASE: ELLO) (“Ellomay” or the “Company”), a renewable energy and power generator and developer of renewable energy and power projects in Europe, USA and Israel, today announced that it executed an agreement (the “Agreement”) to sell its holdings in the 9 MW solar facility located… Continue reading Ellomay Capital Enters into an Agreement to Sell the Talmei Yosef Solar Facility
Driver Injured in First Cybertruck Crash
It was only a matter of time before the first Tesla Cybertruck was involved in a collision. And just before the year drew to a close, a Toyota Corolla crashed into a Cybertruck that was traveling along a road near Palo Alto, California — an accident that’s attracted immense scrutiny due to the Cybertruck’s unconventional and… Continue reading Driver Injured in First Cybertruck Crash
BELOVED AFFIRM ORIGINALS SERIES “GOING HOME” RETURNS TO GREAT AMERICAN PURE FLIX FOR SECOND COMPELLING SEASON, CELEBRATING THE JOURNEY OF LIFE
Going Home premiered on Great American Pure Flix in June of 2022 with the show’s first season and quickly became a member favorite. Creator Dan Merchant returns as the AFFIRM Originals series’ showrunner and lead director. Cynthia Geary once again stars as Charley Copeland, a hospice nurse who sees her role as a calling from God… Continue reading BELOVED AFFIRM ORIGINALS SERIES “GOING HOME” RETURNS TO GREAT AMERICAN PURE FLIX FOR SECOND COMPELLING SEASON, CELEBRATING THE JOURNEY OF LIFE
Tracing generative AI’s wild ride in 2023 and what it means for 2024
ChatGPT was well on its way to becoming a household name even before 2023 kicked off. Just weeks after the Nov. 30 launch of the generative artificial intelligence-powered chatbot, OpenAI, the non-profit behind ChatGPT, was projected to rake in as much as $1 billion in revenue in 2024, sources told Reuters at the time. The so-called large… Continue reading Tracing generative AI’s wild ride in 2023 and what it means for 2024
Intensity Therapeutics Provides Business Update Reflecting Progress in Phase 3 Sarcoma Program
FDA provides “Study May Proceed” letter for open-label, randomized phase 3 protocol in soft tissue sarcoma, and plans to initiate phase 3 study in first half of 2024 SHELTON, Conn., Jan. 3, 2024 /PRNewswire/ — Intensity Therapeutics, Inc. (“Intensity” or the “Company”) (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development… Continue reading Intensity Therapeutics Provides Business Update Reflecting Progress in Phase 3 Sarcoma Program
Global Times: China practices wise foreign policy in managing relations
BEIJING, Jan. 3, 2024 /PRNewswire/ — Editor’s Note: In 2023, the world continued to witness significant changes and turbulence. As we have entered into 2024, we conducted in-depth interviews with leading strategists from various countries and regions to gather their perspectives on the prominent global issues of 2023 and China’s role in addressing them as… Continue reading Global Times: China practices wise foreign policy in managing relations